Merck & Co., Inc. (MRK)
NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
As of 02:50PM EDT. Market open.
| Previous Close | 127.51 |
| Open | 127.18 |
| Bid | 127.58 x 1000 |
| Ask | 127.60 x 900 |
| Day's Range | 126.76 - 127.73 |
| 52 Week Range | 99.14 - 133.10 |
| Volume | |
| Avg. Volume | 8,241,765 |
| Market Cap | 323.063B |
| Beta (5Y Monthly) | 0.40 |
| PE Ratio (TTM) | 140.15 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.08 (2.42%) |
| Ex-Dividend Date | Mar 14, 2024 |
| 1y Target Est | N/A |
- Business Wire
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
RAHWAY, N.J., May 01, 2024--Merck Announces KEYNOTE-811 Trial Met Dual Primary Endpoint as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or GEJ Cancer
- Business Wire
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
RAHWAY, N.J., April 29, 2024--Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
- Business Wire
Merck Announces First-Quarter 2024 Financial Results
RAHWAY, N.J., April 25, 2024--Merck Announces First-Quarter 2024 Financial Results
© 2024 Yahoo. All rights reserved.